Generic Version of Semaglutide on the Way
Prescription referral service PharmaGiant.com has announced it will soon offer a generic version of semaglutide. The move is expected to significantly impact the high-cost diabetes and weight management drug market, where affordability has been a major barrier to access.
The active ingredient, semaglutide, is the powerhouse behind brand-name drugs like Ozempic and Wegovy. Without insurance, the list price for these medications can be steep, with Wegovy around $1,350 and Ozempic near $1,028 for a month's supply. Even with manufacturer discounts for cash-paying customers, the cost remains several hundred dollars per month. The introduction of generics hinges on the expiration of patents held by Novo Nordisk. While some key patents are set to expire in countries like India, Brazil, and Canada around March 2026, the main patents in the United States are not expected to expire until 2031-2032. This creates a staggered timeline for when cheaper, FDA-approved generics will become available globally. In India, the patent expiry is anticipated to slash costs by as much as 85-90%, potentially reducing the monthly price to a fraction of what branded versions cost. Several Indian pharmaceutical companies, including Sun Pharma and Dr. Reddy's Laboratories, are gearing up to launch their generic versions as soon as the patent expires. It's crucial to distinguish between an FDA-approved generic and compounded semaglutide. Compounded versions are custom-mixed by pharmacies and are not FDA-approved for safety, quality, or effectiveness. An approved generic, however, must be "bioequivalent" to the brand-name drug, meaning it works in the same way and is just as safe and effective. The FDA's generic drug approval process is thorough, requiring manufacturers to demonstrate that their product is pharmaceutically equivalent to the brand-name drug. This abbreviated process doesn't require repeating extensive clinical trials but ensures the generic is manufactured correctly and consistently. The arrival of generic semaglutide is expected to dramatically increase access for patients currently priced out of treatment. Analysts predict the market for these drugs could double within a year of generics becoming available in regions like India, due to the significant drop in price and rising demand.
